ACELYRIN Inc
NASDAQ:SLRN
ACELYRIN Inc
Cash from Financing Activities
ACELYRIN Inc
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
ACELYRIN Inc
NASDAQ:SLRN
|
Cash from Financing Activities
$568.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$5.2B
|
CAGR 3-Years
35%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-5%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$3.4B
|
CAGR 3-Years
27%
|
CAGR 5-Years
15%
|
CAGR 10-Years
-1%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
-$9.4B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
10%
|
CAGR 10-Years
-13%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$1.5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$2.2B
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-54%
|
CAGR 10-Years
-26%
|
|
ACELYRIN Inc
Glance View
ACELYRIN Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Agoura Hills, California and currently employs 51 full-time employees. The company went IPO on 2023-05-05. ACELYRIN, INC. is a late-stage clinical biopharmaceutical company. The firm is focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. Its initial focus is on the treatment of diseases with pathology related to excess activation of the immune system. The Company’s lead product candidate is izokibep, a small protein therapeutic designed to inhibit anti-interleukin (IL)-17A with high potency through tight binding affinity and the potential for robust tissue penetration due to its small molecular size, about one-tenth the size of a monoclonal antibody. The company is also advancing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against the insulin-like growth factor 1 receptor (IGF-1R). Lonigutamab has shown high potency against IGF-1R in both binding and functional laboratory assays. In addition, the Company is developing SLRN-517, which is a fully human IgG1 monoclonal antibody targeting c-KIT.
See Also
What is ACELYRIN Inc's Cash from Financing Activities?
Cash from Financing Activities
568.4m
USD
Based on the financial report for Dec 31, 2023, ACELYRIN Inc's Cash from Financing Activities amounts to 568.4m USD.
What is ACELYRIN Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 1Y
107%
Over the last year, the Cash from Financing Activities growth was 107%.
You don't have any saved screeners yet